Role of Prochlorperazine in Vertigo Treatment

Introduction to Vertigo Management

• The American Academy of Otolaryngology-Head and Neck Surgery recommends against routine treatment of vertigo with vestibular suppressant medications like prochlorperazine 1, 2

Mechanism and Classification

• Prochlorperazine is a phenothiazine antipsychotic that works by inhibiting dopamine receptors in the brain, primarily reducing nausea and vomiting rather than treating the underlying cause of vertigo 3
• It belongs to the class of vestibular suppressant medications, which can temporarily relieve symptoms but do not address the root cause of vertigo 1, 2

Evidence-Based Recommendations Against Routine Use

• Clinical practice guidelines from the American Academy of Otolaryngology-Head and Neck Surgery explicitly recommend against routine treatment of vertigo with vestibular suppressant medications like prochlorperazine 1, 2
• There is no evidence in the literature suggesting that vestibular suppressant medications are effective as definitive, primary treatment for vertigo, particularly for benign paroxysmal positional vertigo (BPPV) 1, 4

Limited Appropriate Clinical Applications

• Prochlorperazine may be used for short-term management of severe nausea or vomiting in patients with vertigo who are severely symptomatic 1, 2
• It may be considered as a temporary measure for patients who refuse other treatment options or require symptom relief before definitive treatment can be provided 2

Potential Adverse Effects

• Prochlorperazine can cause significant side effects including drowsiness, cognitive deficits, and interference with driving or operating machinery 2
• Vestibular suppressant medications are a significant independent risk factor for falls, especially in elderly patients 2
• The medication may decrease diagnostic sensitivity during Dix-Hallpike maneuvers due to vestibular suppression, potentially interfering with proper diagnosis 1

Preferred Treatment Approaches for Vertigo

• For BPPV, particle repositioning maneuvers (such as the Epley maneuver) are the recommended first-line treatment rather than medications 1, 2
• Studies have shown that particle repositioning maneuvers have substantially higher treatment responses (78.6%-93.3% improvement) compared with medication alone (30.8% improvement) 2
• Patients should be reassessed within 1 month after initial treatment to confirm symptom resolution 1

Special Considerations

• In specific conditions like Fabry disease with vertigo symptoms, prochlorperazine may be considered for managing associated nausea 5
• For gastroparesis-related vertigo and nausea, prochlorperazine (5–10 mg four times daily) may be considered as part of symptomatic management 3